ID: MRFR/HC/5058-HCR | February 2021 | Region: Global | 90 pages
The market of atrial fibrillation is expected to grow significantly over the forecast period. It is estimated that the atrial fibrillation market is expected to reach USD 11123.8 million at a CAGR 11.2 % during the forecast period of 2018–2023. Atrial fibrillation is an ailment in which the heart beats irregularly, unlike the usual heartbeat. The upper chambers of the heart, the atria quiver in a very rapid pattern and thus the blood flow slows down or stagnates. The ventricles also beat unevenly and do not push blood around the body as efficiently.
Factors such as growing geriatric population and rise in medical tourism are expected to drive the growth of the market. According to the Centers for Disease Control and Prevention, more than 750,000 hospitalizations occur each year because of AFib in the US and the condition contributes to an estimated 130,000 deaths each year. Also, Increased incidence of risk factors such as obesity, hypertension, metabolic syndrome, and diabetes propel atrial fibrillation market growth. Moreover, in September 2018, assets of Pioneer Medical Devices AG were acquired by Vanguard AG. Assets of Pioneer Medical Devices AG included systems processor of highly complex medical devices mainly used in cardiology. By doing this, Vanguard AG will expand its product portfolio of complex medical devices for intervention therapy and minimally invasive surgeries.
Moreover, high recurrence and complication rates, coupled with the lack of technical personnel specialized in atrial fibrillation may hamper the market growth during the assessment period. Also, unavailability of high-quality data and clinical guidelines about atrial fibrillation may curb the growth of the market.
Johnson & Johnson Services, Inc., Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure, Inc., CardioFocus, Osypka AG, Siemens AG, Biosense Webster, Inc., Sichuan Jinjiang Electronic Science and Technology Co., Ltd., CathRx Ltd., and Vanguard AG are some of the key players in the global atrial fibrillation market.
The global atrial fibrillation market has been segmented into type, treatment, and end-user.
The market, on the basis of type, has been segmented into paroxysmal atrial fibrillation, persistent atrial fibrillation, and permanent atrial fibrillation.
The market, on the basis of treatment, has been segmented into medications, non-surgical procedures, and surgical procedures.
The market, based on medications, has been segmented blood thinners, rate controllers, and rhythm controllers.
The atrial fibrillation market, based on non-surgical procedures, has been segmented into electrical cardioversion and catheter ablation.
Catheter ablation segment is projected to hold the largest share in the market, as it is a minimally invasive type of surgery which is the most preferred and used, as it lessens the risk of complications, whereas electric cardioversion is estimated to be the fastest growing segment because of its specificity of treatment and decreased recurrence rate.
The market, based on surgical procedures, has been segmented into pacemaker implantation and open-heart maze procedure.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The atrial fibrillation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The atrial fibrillation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Atrial Fibrillation Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is anticipated to dominate the global atrial fibrillation market owing to a the rise in the adoption of innovative technologies and procedures for the treatment of atrial fibrillation, and advanced healthcare facilities and infrastructure. According to the Centers for Disease Control and Prevention in 2017, an estimated 2.7 to 6.1 million people in the United States have atrial fibrillation (AFib).
Europe is expected to hold the second largest position in the global atrial fibrillation market. The market growth in this region is attributed to the availability of funds for research, and favorable reimbursement scenario. According to a journal published by European Heart Network, approximately 10 million people in Europe live with the atrial fibrillation condition.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population susceptible to cardiac diseases, continuously developing economies and rising prevalence of cardiovascular diseases.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to growing government initiatives for the healthcare sector.
Global Atrial Fibrillation Market, by Type
Global Atrial Fibrillation Market, by Treatment
Global Atrial Fibrillation Market, by End-user
Global Market, by Region
|Market Size||USD 11123.8 million|
|CAGR||11.2 % (2018–2023)|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Type, Treatment, End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Johnson & Johnson Services, Inc., Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure, Inc., CardioFocus, Osypka AG, Siemens AG, Biosense Webster, Inc., Sichuan Jinjiang Electronic Science and Technology Co., Ltd., CathRx Ltd., and Vanguard AG|
|Key Market Opportunities||Joint ventures, strategic alliances, mergers and acquisitions and new product developments|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
on the basis of treatment, the market of atrial fibrillation has been segmented into medications, non-surgical procedures, and surgical procedures and medications further segmented into blood thinners, rate controllers, and rhythm controllers.
Increasing prevalence of AF cases among elderly population and increasing technological developments are the major tailwinds pushing the growth of the global Atrial fibrillation market.
North America holds the largest share in the global atrial fibrillation market, followed by Europe and the Asia Pacific, respectively.
Carima, Agricore, Biosense Webster, St. Jude Medical, and Medtronic, are some of the major players operating in the global atrial fibrillation market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global atrial fibrillation market adopt to gain a larger competitive advantage.
Catheter ablation, a sub-segment of surgical products holds the majority shares in the global atrial fibrillation market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.